title: Management and diagnostic guidelines for fungal diseases in infectious diseases and clinical microbiology: critical appraisal.
abstract: Invasive fungal infections (IFIs) are life-threatening conditions that require rapid diagnostic and optimal management to mitigate their high morbidity and mortality rate. They are also associated with a high economic burden, owing to prolonged hospitalization, the need for intensive supportive care, and the consumption of costly new antifungal agents. To address these issues, several international organizations have proposed guidelines for the management of IFIs. The consistency and reliability of these guidelines have rarely been assessed. This article is a review of the differences between the recommendations of the Infectious Diseases Society of America, the European Conference on Infection in Leukaemia, and the European Society of Clinical Microbiology and Infectious Diseases, and will focus on targeted treatment and diagnostic procedures. Although the conclusions of the three groups of experts are in many points similar we outlined some important differences in the methodology and conclusions of ESCMID. The use of these guidelines has the potential to enhance the management of fungal infections but is probably currently suboptimal.
authors.affiliation: Department of Internal Medicine II, Universitätsklinikum, Julius Maximilian's University, Würzburg, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Leroux
authors.forename: A J
authors.initials: AJ
authors.lastname: Ullmann
mesh_terms: D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000175:diagnosis / Q000188:drug therapy; D058365:Candidiasis, Invasive / Q000175:diagnosis / Q000188:drug therapy; D019317:Evidence-Based Medicine; D006801:Humans; D009091:Mucormycosis / Q000175:diagnosis / Q000188:drug therapy; D009181:Mycoses / Q000175:diagnosis* / Q000188:drug therapy*; D017410:Practice Guidelines as Topic / Q000592:standards*; D011743:Pyrimidines / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole
keywords: Aspergillus; Candida; Mucormycosis; Treatment